NXL
Nexalin Technology, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$5.06
−5.60%Sep 2, 2026, 20:54 UTC
Carolyn Shelton departed as Senior Vice President of Quality, Regulatory, and Clinical Affairs at Nexalin Technology, Inc., effective August 28, 2026, with severance including one month of base salary, a $20,000 bonus for 2026, accelerated stock option vesting, and health insurance subsidy through September 30, 2026.
Aug 20, 2026, 00:00 UTC
Nexalin Technology, Inc. signed a securities purchase agreement on August 19, 2026 to issue and sell 2,419,355 shares of common stock at $0.31 per share in a registered direct offering, with concurrent warrants to purchase up to 1,209,677 shares at $0.50 per share, expecting gross proceeds of approximately $750,000.
Aug 20, 2026, 00:00 UTC
Nexalin Technology, Inc. signed an Any Market Purchase Agreement with Alumni Capital LP on August 19, 2026, granting the company the right to sell up to $15 million of common stock in a series of purchases, with the agreement expiring December 31, 2027.
Aug 17, 2026, 00:00 UTC
Nexalin Technology, Inc. received a notice from Nasdaq on 2026-08-14 for non-compliance with the Stockholders' Equity Requirement (Rule 5550(b)(1)) and requested a hearing before the Nasdaq Hearing Panel to present its remediation plan.
Jun 29, 2026, 18:45 UTC
The US Patent and Trademark Office issued US Patent 12,629,519 to Nexalin Technology Inc for its non-invasive deep-brain neurostimulation method targeting insomnia, anxiety, and depression.
Source:Jun 10, 2026, 13:15 UTC
Nexalin Technology reported clinical trial results in Brazil to support the launch of its DIFS 15 mA 77.5 Hz treatment platform.
Source: